Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aventis pharma limited, united kingdom - triamcinolone acetonide - nasal spray - 55 µg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

napp pharmaceuticals limited, united kingdom - formoterol , fluticasone - inhaler - 250/10 mcg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

napp pharmaceuticals limited, united kingdom - formoterol fumarate ,fluticasone propionate - inhaler - 125/5 mcg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

napp pharmaceuticals limited, united kingdom - formoterol fumarate ,fluticasone propionate - inhaler - 50/5 mcg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aventis pharma limited - docetaxel - solution - 80 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aventis pharma limited, united kingdom - adenosine - solution for injection - 3 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aventis pharma limited, united kingdom - adenosine - solution for injection - 3 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aventis pharma limited, united kingdom - danazol - capsule - 100 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aventis pharma limited, united kingdom - danazol - capsule - 200 mg

European Union - English - EMA (European Medicines Agency)

aventis pharma s.a. - telithromycin - sinusitis; tonsillitis; bronchitis, chronic; pharyngitis; community-acquired infections; pneumonia, bacterial - antibacterials for systemic use, - when prescribing ketek, consideration should be given to official guidance on the appropriate use ofantibacterial agents and the local prevalence of resistance.ketek is indicated for the treatment of the following infections:in patients of 18 years and oldercommunity-acquired pneumonia, mild or moderate.when treating infections caused by known or suspected beta-lactam- and / or macrolide-resistant strains (according to history of patients or national and / or regional resistance data) covered by the antibacterial spectrum of telithromycin:acute exacerbation of chronic bronchitis;acute sinusitis;in patients of 12 years and oldertonsillitis / pharyngitis caused by streptococcus pyogenes, as an alternative when beta-lactam antibiotics are not appropriate in countries / regions with a significant prevalence of macrolide-resistant s. pyogenes, when mediated by ermtr or mefa.